Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
NCT03680365
Last updated date
ABOUT THIS STUDY
The purpose of this study is to improve the understanding of the treatment goals that a
person with Duchenne Muscular Dystrophy (DMD) or the caregiver may be most interested in,
based on the severity of the person's disease. Data will be collected by online survey when
the participant accepts the study invitation ("RSVP questionnaire") and telephone interview
on the functional burden and self-identified treatment goals from the perspective of people
with DMD and their caregivers. Interviews will be analyzed to help identify things important
to Duchenne families to measure in clinical trials and to inform the selection of key
concepts of interest and development of future clinical outcome measures, including observer
reported outcomes/patient reported outcomes. The study will be conducted in the United States
and will enroll between 45 and 120 participants 11 years or older living with DMD as well as
their caregivers. The time commitment for the online survey and the telephone interview is
about one hour. It is anticipated that the entire study will be completed within one year.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Duchenne Muscular Dystrophy, Dependency Burden, Disability Physical, Disease Management, Impairment, Rare Diseases
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
11 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
1. Participant must be a person with DMD who is 11 years or older or The parent/legal guardian of a person with DMD who is under the age of 18 years.
2. Confirmed diagnosis of DMD with written proof of disease provided
3. Resident of the U.S.
4. Able to read, write and communicate in English
5. Able to grant informed consent
6. Willing to participate in a 45 minute telephone interview
7. Ability to view or receive a document from the interviewer before or during the interview (web browser, ability to receive a text, fax or document by mail)
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
1. Inability to meet any of the inclusion criteria
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Clinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Duchenne Muscular Dystrophy, Dependency Burden, Disability Physical, Disease Management, Impairment, Rare DiseasesYour Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
NCT03680365
- Eagan, Minnesota
ALL GENDERS
11 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | |||||
|---|---|---|---|---|---|
| Brief Title | Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families | ||||
| Official Title | Your Voice; Impact of DMD. A Qualitative Assessment of the Impact of DMD on the Lives of Families | ||||
| Brief Summary | The purpose of this study is to improve the understanding of the treatment goals that a person with Duchenne Muscular Dystrophy (DMD) or the caregiver may be most interested in, based on the severity of the person's disease. Data will be collected by online survey when the participant accepts the study invitation ("RSVP questionnaire") and telephone interview on the functional burden and self-identified treatment goals from the perspective of people with DMD and their caregivers. Interviews will be analyzed to help identify things important to Duchenne families to measure in clinical trials and to inform the selection of key concepts of interest and development of future clinical outcome measures, including observer reported outcomes/patient reported outcomes. The study will be conducted in the United States and will enroll between 45 and 120 participants 11 years or older living with DMD as well as their caregivers. The time commitment for the online survey and the telephone interview is about one hour. It is anticipated that the entire study will be completed within one year. | ||||
| Detailed Description | Not Provided | ||||
| Study Type | Observational | ||||
| Study Design | Observational Model: Case-Only Time Perspective: Cross-Sectional | ||||
| Target Follow-Up Duration | Not Provided | ||||
| Biospecimen | Not Provided | ||||
| Sampling Method | Non-Probability Sample | ||||
| Study Population | The study will be conducted in individuals 11 years or older living with Duchenne Muscular Dystrophy as well caregivers. | ||||
| Condition |
| ||||
| Intervention | Not Provided | ||||
| Study Groups/Cohorts | Not Provided | ||||
| Publications * |
| ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||
| Recruitment Information | |||||
| Recruitment Status | Completed | ||||
| Actual Enrollment | 60 | ||||
| Original Estimated Enrollment | 120 | ||||
| Actual Study Completion Date | March 15, 2019 | ||||
| Actual Primary Completion Date | March 15, 2019 (Final data collection date for primary outcome measure) | ||||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria: 1. Inability to meet any of the inclusion criteria | ||||
| Sex/Gender |
| ||||
| Ages | 11 Years and older (Child, Adult, Older Adult) | ||||
| Accepts Healthy Volunteers | Yes | ||||
| Contacts | Contact information is only displayed when the study is recruiting subjects | ||||
| Listed Location Countries | United States | ||||
| Removed Location Countries | |||||
| Administrative Information | |||||
| NCT Number | NCT03680365 | ||||
| Other Study ID Numbers | Jett 0001 | ||||
| Has Data Monitoring Committee | No | ||||
| U.S. FDA-regulated Product |
| ||||
| IPD Sharing Statement |
| ||||
| Responsible Party | Jett Foundation, Inc. | ||||
| Study Sponsor | Jett Foundation, Inc. | ||||
| Collaborators |
| ||||
| Investigators |
| ||||
| PRS Account | Jett Foundation, Inc. | ||||
| Verification Date | March 2019 | ||||